Related Experiment Video

Updated: Oct 16, 2026

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases
03:22

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases

Published on: March 1, 2024

Advances in antimicrobial therapy for respiratory tract infections

D M Mushatt1

  • 1Tulane University School of Medicine, Department of Medicine, New Orleans, Louisiana 70112, USA.

Current Opinion in Pulmonary Medicine
|April 27, 2000
PubMed

Insights

Recent advances in antimicrobial therapy offer hope for treating respiratory infections like pneumonia and influenza. New antivirals and immunomodulatory therapies may lead to shorter treatments and reduced healthcare costs.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Pharmacology

Background:

  • Respiratory infections, including pneumonia and influenza, represent a significant public health burden in the US.
  • Pneumonia is the primary infectious cause of death, and influenza incurs substantial annual costs for Medicare.

Purpose of the Study:

  • To review recent advancements in antimicrobial therapy for respiratory tract infections.
  • To highlight efforts in reducing treatment duration and costs for pneumonia.
  • To discuss new antiviral treatments for influenza and the growing scientific interest in alternative medicine.

Main Methods:

  • Literature review of recent studies on antimicrobial therapies for respiratory infections.
  • Analysis of new drug classes and treatment strategies.
  • Examination of emerging research in immunomodulatory therapies.

Main Results:

  • Introduction of a new class of antiviral medications for influenza treatment.
  • Ongoing efforts to shorten pneumonia treatment length and decrease associated costs.
  • Increased scientific investigation into alternative medicine for respiratory conditions.

Conclusions:

  • Antimicrobial agents are crucial but not sufficient for comprehensive respiratory infection management.
  • Emerging immunomodulatory therapies suggest a future of multifaceted treatment approaches.
  • Continued research is vital for developing more effective and cost-efficient strategies against respiratory pathogens.

More Related Videos

Rapid Point-of-Care Detection of Pathogens for Lower Respiratory Tract Infections in ICU Patients07:16

Rapid Point-of-Care Detection of Pathogens for Lower Respiratory Tract Infections in ICU Patients

Published on: September 19, 2026

Related Concept Videos

Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Microbiota of the Respiratory Tract01:29

Microbiota of the Respiratory Tract

The human respiratory tract, comprising the upper and lower segments, serves as a critical interface with the external environment. The upper respiratory tract (URT)—including the nostrils, sinuses, pharynx, and oropharynx—is heavily colonized by microbes, while the lower respiratory tract (LRT), composed of the larynx, trachea, bronchi, and lungs, was long thought to be sterile. However, recent molecular studies have revealed that the lungs are not devoid of microbes but act more like...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...